AXSM Valuation

Axsome Therapeutics Inc

Add to Watchlist

Advanced Chart

121.150

+4.84(4.161%)1D

Overview
Forecast
Valuation
Earnings

AXSM Relative Valuation

AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXSM is overvalued; if below, it's undervalued.

Historical Valuation

Axsome Therapeutics Inc (AXSM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.86 is considered Undervalued compared with the five-year average of -18.77. The fair price of Axsome Therapeutics Inc (AXSM) is between 677.26 to 701.40 according to relative valuation methord. Compared to the current price of 121.15 USD , Axsome Therapeutics Inc is Undervalued By 82.11%.

Relative Value

Fair Zone

677.26-701.40

Current Price：121.15

82.11%

Undervalued

-58.47

Trailing

Forward

-162.85

EV/EBITDA

Axsome Therapeutics Inc. (AXSM) has a current EV/EBITDA of -162.85. The 5-year average EV/EBITDA is -32.15. The thresholds are as follows: Strongly Undervalued below -104.23, Undervalued between -104.23 and -68.19, Fairly Valued between 3.89 and -68.19, Overvalued between 3.89 and 39.92, and Strongly Overvalued above 39.92. The current Forward EV/EBITDA of -162.85 falls within the Strongly Undervalued range.

-54.65

EV/EBIT

Axsome Therapeutics Inc. (AXSM) has a current EV/EBIT of -54.65. The 5-year average EV/EBIT is -19.44. The thresholds are as follows: Strongly Undervalued below -40.35, Undervalued between -40.35 and -29.89, Fairly Valued between -8.98 and -29.89, Overvalued between -8.98 and 1.47, and Strongly Overvalued above 1.47. The current Forward EV/EBIT of -54.65 falls within the Strongly Undervalued range.

7.86

Axsome Therapeutics Inc. (AXSM) has a current PS of 7.86. The 5-year average PS is 1662.19. The thresholds are as follows: Strongly Undervalued below -10782.46, Undervalued between -10782.46 and -4560.14, Fairly Valued between 7884.51 and -4560.14, Overvalued between 7884.51 and 14106.84, and Strongly Overvalued above 14106.84. The current Forward PS of 7.86 falls within the Historic Trend Line -Fairly Valued range.

3318.64

P/OCF

Axsome Therapeutics Inc. (AXSM) has a current P/OCF of 3318.64. The 5-year average P/OCF is 48.68. The thresholds are as follows: Strongly Undervalued below -910.97, Undervalued between -910.97 and -431.15, Fairly Valued between 528.51 and -431.15, Overvalued between 528.51 and 1008.33, and Strongly Overvalued above 1008.33. The current Forward P/OCF of 3318.64 falls within the Strongly Overvalued range.

3394.85

P/FCF

Axsome Therapeutics Inc. (AXSM) has a current P/FCF of 3394.85. The 5-year average P/FCF is 45.63. The thresholds are as follows: Strongly Undervalued below -939.23, Undervalued between -939.23 and -446.80, Fairly Valued between 538.05 and -446.80, Overvalued between 538.05 and 1030.48, and Strongly Overvalued above 1030.48. The current Forward P/FCF of 3394.85 falls within the Strongly Overvalued range.

Axsome Therapeutics Inc (AXSM) has a current Price-to-Book (P/B) ratio of 79.29. Compared to its 3-year average P/B ratio of 42.33 , the current P/B ratio is approximately 87.31% higher. Relative to its 5-year average P/B ratio of 43.46, the current P/B ratio is about 82.43% higher. Axsome Therapeutics Inc (AXSM) has a Forward Free Cash Flow (FCF) yield of approximately -2.05%. Compared to its 3-year average FCF yield of -3.70%, the current FCF yield is approximately -44.59% lower. Relative to its 5-year average FCF yield of -4.63% , the current FCF yield is about -55.77% lower.

79.29

P/B

Median3y

42.33

Median5y

43.46

-2.05

FCF Yield

Median3y

-3.70

Median5y

-4.63

Competitors Valuation Multiple

The average P/S ratio for AXSM's competitors is 164.89, providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of 7.86, which is -95.23% above the industry average. Given its robust revenue growth of 72.13%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AXSM.O

Axsome Therapeutics Inc

Avidity Biosciences Inc

Telix Pharmaceuticals Ltd

CRISPR Therapeutics AG

Performance Decomposition

Market capitalization of AXSM increased by 36.34% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 87.17M to 150.04M.

The secondary factor is the P/E Change, contributed 29.09%to the performance.

Overall, the performance of AXSM in the past 1 year is driven by Revenue Growth. Which is more sustainable.

72.13%

87.17M → 150.04M

Revenue Growth

-64.88%

-91.03 → -31.97

Margin Expansion

29.09%

-17.79 → -22.97

P/E Change

36.34%